HER2-Low Should Not Be a Distinct Subtype of Breast Cancer, Researchers Say There were no significant differences in outcomes between patients with low HER2 expression and those with no HER2 expression, after adjusting for hormone receptor status.
Ceralasertib Provides No Benefit in Advanced Triple-Negative Breast Cancer Combining ceralasertib with olaparib did not improve response rates or progression-free survival.
Combination Produces Longest Survival to Date in Treatment-Naïve Advanced Breast Cancer Adding ribociclib to fulvestrant prolonged overall survival by 15.8 months.
Patritumab Deruxtecan Yields Responses in HR+/HER2- Breast Cancer Patritumab deruxtecan produced “clinically meaningful” responses, according to researchers.
